Global Health Limited – Investor Presentation Summary

Key Operational Highlights

  • Highest ever quarterly total income of ₹13,262 million achieved in Q1 FY27.
  • In-patient count increased by 27.7% year-over-year to 60,214 patients.
  • Out-patient count increased by 34.5% year-over-year to 1,100,928 patients.
  • Occupied bed days increased by 21.1% year-over-year to 173,064 days.
  • Network occupancy stood at approximately 63% on increased bed capacity (66% excluding Noida).
  • 72 new beds were added across the network during the quarter (21 at Lucknow, 51 at Noida).
  • International Patients Revenue increased by 23.0% year-over-year to ₹782 million.
  • OPD Pharmacy (Hospital & Retail) revenue increased by 50.9% year-over-year to ₹609 million.
  • 70+ doctors were onboarded in Q1 FY27 across Medanta network hospitals, including 50+ senior clinicians.

Key drivers of operational performance: Growth primarily led by increase in patient volumes and realization, expansion of bed capacity, and strengthening of clinical capabilities across hospitals.

Segment-wise Performance

  • Cluster 1 hospitals (Gurugram, Indore, Ranchi): Consistent growth with improved margins (specific figures not provided in presentation).
  • Cluster 2 hospitals (Lucknow, Patna, Noida): Strong revenue and EBITDA growth continues (specific figures not provided in presentation).

Explanation of significant changes in segment performance: Not Specified

Financial Highlights

Revenue: ₹13,262 million

EBITDA: ₹3,153 million (including Noida)

EBITDA ex-Noida: ₹3,201 million

PAT: ₹1,573 million

EBITDA Margin: 23.8% (including Noida), 25.8% (ex-Noida)

PAT Margin: 11.9%

YoY/QoQ comparison: Revenue growth of 26.2% YoY; EBITDA growth of 23.5% YoY (including Noida); PAT decreased by 1.1% YoY compared to ₹1,590 million in Q1 FY26.

Drivers of financial performance: Growth primarily led by increase in patient volumes and realization. Q1 FY26 had a non-recurring exceptional income of ₹196 million primarily due to reversal of potential interest liability on EPCG following transfer of EPCG license from MHPL to GHL.

Comparison to market estimates: Not Specified

Key Risks: Not Specified

Geographical Revenue Split

Domestic vs Export/Regional Revenue: Not Specified

Regional Breakdown: Not Specified

Balance Sheet Snapshot

Net Debt/Equity: Not Specified

Reserves: Not Specified

Current Assets/Liabilities: Not Specified

Working Capital/Leverage Metrics: Not Specified

Financial Health Insights: Not Specified

Capex & Cash Flow Health

Capital Expenditure: ₹1,610 million incurred in Q1 FY2027; Total capex of ~₹48,500 million planned for next 5 years

Free Cash Flow: Not Specified

Operating Cash Flow: Not Specified

Net Debt Movement: Not Specified

Investment Rationale: Capex to be funded by combination of Debt funding and internal accruals for expansion projects.

Strategic & R&D Initiatives

Investments in Innovation: New medical equipment deployed including MISSO Ortho Robotic System (Gurugram), Stealth Station S8 - Surgical Navigation System (Lucknow), J&J VELYS Orthopaedic Surgical Robot (Lucknow & Patna).

Expected impact on growth: Not Specified

Strategic Rationale: Strengthening the core and building strong pipeline for growth through capacity expansion and technology upgrades.

Industry Trends & Business Environment

Macro/Industry Trends: Not Specified

Impact on Company: Not Specified

Management Commentary & Growth Outlook

Strategic Outlook: Medanta is well placed to deliver sustainable growth while maintaining its core values of patient centric care and clinical leadership and quality in existing and new hospitals.

FY Guidance: Not Specified

Market Share Targets: Not Specified

Risks and Opportunities: Not Specified

Additional Headings

Medanta Noida Update
  • Noida hospital generated Total Income of ₹855 million in Q1 FY27
  • EBITDA loss narrowed to ₹49 million in Q1 FY27 from ₹236 million in Q4 FY26
  • Operational beds increased to 433 (of 550 planned capacity)
  • Total census beds increased to 323 from 274 in previous quarter
  • 51 beds added on 9th Floor A-Wing during quarter
  • All major Insurance & PSU empanelment completed
  • Performed 5,000+ procedures in Q1 FY27
Clinical Achievements Q1 FY27
  • Successful treatment of critically ill lung adenocarcinoma patient using VV-ECMO-supported therapeutic bronchoscopy at Gurugram
  • Successful treatment of rare DYT1 dystonia in 12-year-old patient using Deep Brain Stimulation at Gurugram
  • Robotic-assisted paraesophageal hernia repair performed at Noida
  • Lucknow crossed milestone of 1,000 joint replacement surgeries using advanced robotic technology
  • Lucknow became first private healthcare institution in Uttar Pradesh to perform Whole Lung Lavage for Pulmonary Alveolar Proteinosis
  • Patna performed first Transarterial Chemoembolization procedure for hepatocellular carcinoma
  • Patna successfully treated critically ill 10-month-old infant with hepatoblastoma using Continuous Renal Replacement Therapy
Expansion Projects Update
  • Noida: 51 beds added, total capacity 550 beds (433 operational)
  • Lucknow: 21 beds added, total bed count 778 beds (950 planned)
  • South Delhi: 400-bed project in partnership with DLF, construction in progress
  • Pitampura, New Delhi: Signed O&M Agreement for ~750 bed hospital, building plan under preparation
  • Mumbai: Land acquired October 2024, approvals in process
  • Guwahati, Assam: Land acquisition completed, bed capacity increased from 400 to 650 beds
  • Varanasi: 400-bed project announced March 2026, building plans under preparation
  • Indore Cancer Unit: 80-bed cancer hospital to be operationalized in Q2/Q3 FY27
Continuity of Care Network
  • 825+ active touch points and 325+ collection centers across 100+ cities
  • 12 labs and 4 HLMs/RLMs
  • Achieved 1.56 lakh patient bookings (21% YoY growth)
  • 22 operational pharmacies (7 in-hospital, 2 mediclinics, 13 retail)